文献速递心胸血管麻醉

右美托咪定对心脏手术后结局的影响:DOCS随机双盲安慰剂对照试验

Effects of Dexmedetomidine on Outcomes After Cardiac Surgery (DOCS): a randomised double-blind, placebo-controlled trial.
PubMed 文献 · Br J Anaesth · 2025-11-14

DOCS试验在中国9家医院纳入1073例体外循环心脏手术成人,围术期静脉输注右美托咪定0.4 μg kg-1 h-1或生理盐水12小时。主要复合结局(住院死亡和主要并发症)右美组30%对安慰剂组32%(RR 0.93,95%CI 0.72-1.21,P=0.66),住院死亡1.9%对2.8%(OR 0.66,95%CI 0.29-1.49,P=0.32),均无统计学差异。结论:围术期右美托咪定未减少死亡或并发症。

要点

  • 右美托咪定0.4 μg kg-1 h-1围术期输注12小时未降低心脏手术后主要并发症风险。
  • 住院死亡右美组1.9%对安慰剂组2.8%,差异无统计学意义(P=0.32)。
  • 除心脏传导阻滞外,其余主要并发症在两组间无差异,安全性结局无差异。

核心结论

  • 成人体外循环心脏手术围术期使用右美托咪定未减少死亡、并发症或两者复合结局。

研究设计与样本

  • 随机、双盲、安慰剂对照试验,在中国9家医院开展,纳入拟行体外循环心脏手术的成人。
  • 共1073例完成研究(女性46%,平均年龄54岁,范围47-63岁),随机接受右美托咪定0.4 μg kg-1 h-1或生理盐水,麻醉诱导后持续12小时。
  • 共同主要结局为住院死亡和术后主要并发症(包括卒中、心肌梗死、心脏传导阻滞、心脏骤停),按意向性治疗分析。

主要发现

  • 主要并发症:右美组161/536(30%) vs 安慰剂组169/537(32%),RR 0.93(95%CI 0.72-1.21),P=0.66。
  • 住院死亡:右美组10/536(1.9%) vs 安慰剂组15/537(2.8%),OR 0.66(95%CI 0.29-1.49),P=0.32。
  • 除心脏传导阻滞外,其余主要并发症在两组间无差异,安全性和过程指标亦无差异。

临床怎么用

  • 对于体外循环心脏手术成人,不应以降低死亡或主要并发症为目的常规围术期输注右美托咪定0.4 μg kg-1 h-1持续12小时。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Organ dysfunction after cardiac surgery may be reduced by dexmedetomidine. We evaluated whether perioperative dexmedetomidine reduces complications after cardiac surgery with cardiopulmonary bypass. METHODS: In this randomised, double-blind, placebo-controlled trial conducted in nine Chinese hospitals, adults scheduled for cardiac surgery with cardiopulmonary bypass were randomly assigned to receive i.v. dexmedetomidine (0.4 μg kg-1 h-1) or saline (placebo) for 12 h after the induction of anaesthesia. The co-primary outcomes were in-hospital mortality and major complications after surgery (including stroke, myocardial infarction, heart block, cardiac arrest), analysed by intention-to-treat. Secondary outcomes included individual complications. RESULTS: A total of 1073 participants (46% female; mean age: 54 yr [range: 47-63 yr]) completed the study after randomisation. Major complications occurred in 161/536 (30%) participants who received dexmedetomidine, compared with 169/537 (32%) who received saline (relative risk: 0.93 [95% confidence interval: 0.72-1.21]; P=0.66). In addition, 10/536 (1.9%) participants who received dexmedetomidine died in hospital, compared with 15/537 (2.8%) participants who received saline (odds ratio: 0.66 [95% confidence interval: 0.29-1.49]; P=0.32). Major complications, other than heart block, did not differ between participants who received dexmedetomidine, compared with participants who received saline. Safety outcomes and process measures did not differ between participants allocated to dexmedetomidine or saline. CONCLUSIONS: Perioperative use of dexmedetomidine did not reduce death, complications, or both in adults undergoing cardiopulmonary bypass-assisted cardiac surgery. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov (NCT02237495).

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Lei C, Zheng Z, Han J, et al. Effects of Dexmedetomidine on Outcomes After Cardiac Surgery (DOCS): a randomised double-blind, placebo-controlled trial. Br J Anaesth. 2025. PMID: 41238464. doi:10.1016/j.bja.2025.09.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。